Table 4. Clinical and resistance data for non-responders patients after DAAs therapy.
| Characteristics | Patients | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| Age | 56 | 61 | 76 | 57 | 65 | 56 |
| Genotype | 1a | 1a | 1a | 1a | 3a | 3a |
| Group | HCV | HCV | HCV | HCV | HCV | HCV/HIV |
| Therapeutic regimen | S/D/R | S/D/R | S/D/R | S/R | S/R | S/R |
| Therapy duration (weeks) | 24 | 24 | 12 | 12 | 12 | 12 |
| Baseline viral load (Log UI/mL) | 5.0 | 6.8 | 5.7 | 4.85 | 6.86 | 6.36 |
| Hepatic condition | Cirrhotic | Cirrhotic | Cirrhotic | Cirrhotic | Cirrhotic | Cirrhotic |
| Baseline NS5A RASs | - | - | - | Q30Y** | - | A30S** |
| Post-treatment NS5A RASs | - | Y93N | M28T, Q30R, E62D* | Q30Y** | - | A30S** |
| Baseline NS5B RASs | - | - | - | - | - | - |
| Post-treatment NS5B RASs | - | - | - | - | - | - |
S: sofosbuvir; D: daclatasvir; R: ribavirina
*Secondary RASs
**RASs not demonstrated to be clinically relevant due to low evidence in vivo